APP and Alzheimer disease: In a study by Sun et al., six weeks of oral administration of FOS to APP/PSEN1dE9 transgenic mice improved cognitive function and reduced AD-related pathological changes by increasing the expression of synapsin I and postsynaptic density protein 95 (PSD-95).